Cyclooxygenase-2 Expression in Right- and Left-Sided Colon Cancer: A Rationale For Optimization of Cyclooxygenase-2 Inhibitor Therapy

摘要: Abstract Cyclooxygenase-2 (COX-2) has been identified as a potential target for prevention and therapy of human colorectal cancers (CRC) other cancers. Because right-sided colon (RSCCs) exhibit clinicopathologic genetic differences from left-sided (LSCRCs), determination COX-2 status in these subsets CRCs may be clinically relevant designing inhibitor trials CRC subsequent assessment objective therapeutic response to such therapy. Thirty-six primary resection specimens (18 left, 18 right) 36 patients were evaluated. Representative tumor sections subjected immunohistochemical analysis COX-2. A semiquantitative system was used score cytoplasmic immunostaining. The tumors considered positive if > 10% cells showed staining. Clinicopathologic data compared LSCRCs versus RSCCs. All 13 (72%) RSCCs well moderately differentiated. Overall rates positivity the 67% (12 18) 33% (6 18), respectively (P = 0.04). Furthermore, 11 12 (92%) COX-2—positive 3 6 (50%) stage II-IV at resection. associated with advanced 4 (33%) LCRCs had distant metastases. These associations could not evaluated because limited number cases. more frequent expression supports hypothesis that related alterations specific rightor CRCs. Further studies are needed elucidate relationships. Our also suggest stratification into right- important optimal patient selection response.